June 2022 Neurology Recall: Aducanumab's Approval, One Year Later

The June 2022 replay of past episodes showcases a selection of interviews about the impact of the FDA's approval of aducanumab for the treatment of Alzheimer disease (AD). This episode features illuminating conversations with Drs. Gregg Day, Ron Petersen, and Jason Karlawish on the clinical science guiding amyloid-based treatments for AD, the importance of patient participation when considering the use of aducanumab, and the business of Alzheimer disease, respectively. This month's Recall concludes with an interview featuring Pulitzer Prize-winning journalist Pam Belluck on Medicare's limitations on aducanumab coverage.